Today, Kezar Life Sciences announced topline results from the PRESIDIO study, evaluating the efficacy and safety of zetomipzomib in dermatomyositis and polymyositis. In this study, most patients experienced a clinically…
Continue Reading
Join us for MyoCon: TMA’s Global Myositis Patient Conference and World Myositis Day! Register Now!
Today, Kezar Life Sciences announced topline results from the PRESIDIO study, evaluating the efficacy and safety of zetomipzomib in dermatomyositis and polymyositis. In this study, most patients experienced a clinically…
Continue ReadingIn 2022, we will launch this interactive community awareness event in six local communities across the country where an estimated more than 40,000 dedicated participants will work to raise funds…
Continue ReadingCelebrating Community – Click here to join
Continue ReadingClick here for more details
Continue ReadingClick here to register
Continue Reading